Related Experiment Video
Updated: Jun 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study
Christian Fynbo Christiansen1, Steffen Christensen, Frank Mehnert
1Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark. cc@dce.au.dk
Insights
Current glucocorticoid use nearly doubles the risk of developing atrial fibrillation or flutter. This study found a significant association, highlighting potential cardiovascular risks of these medications.
Area of Science:
- Cardiology
- Pharmacology
- Epidemiology
Background:
- Glucocorticoid medications are linked to cardiovascular events like heart attack and stroke.
- Limited data exist on the association between glucocorticoid use and atrial fibrillation or flutter risk.
Purpose of the Study:
- To investigate the association between current and former glucocorticoid use and the risk of developing atrial fibrillation or flutter.
Main Methods:
- A population-based, case-control study in Northern Denmark (1.7 million people) from 1999-2005.
- Included 20,221 patients diagnosed with atrial fibrillation/flutter and 202,130 matched population controls.
- Glucocorticoid prescription data (current/former use) and confounders were analyzed using conditional logistic regression.
Main Results:
- Current glucocorticoid use was associated with a nearly 2-fold increased risk of atrial fibrillation/flutter (adjusted OR, 1.92; 95% CI, 1.79-2.06).
- New users had a higher risk (adjusted OR, 3.62) than long-term users (adjusted OR, 1.66).
- Former glucocorticoid use showed no increased risk (adjusted OR, 1.00).
Conclusions:
- Current glucocorticoid use is significantly associated with an increased risk of atrial fibrillation or flutter.
- The findings underscore the importance of monitoring cardiac health in patients using glucocorticoids.
Background:
Glucocorticoid use is associated with increased risk of myocardial infarction, stroke, and heart failure, but data are limited on the risk of atrial fibrillation or flutter. We examined whether glucocorticoid use is associated with the risk of atrial fibrillation or flutter.
Methods:
For this population-based, case-control study, we identified all patients with a first hospital diagnosis of atrial fibrillation or flutter from January 1, 1999, through December 31, 2005, in Northern Denmark (population, 1.7 million). For each case we selected 10 population controls matched by age and sex. We obtained data on glucocorticoid prescriptions within 60 days (current users) or longer before the index date (former users), comorbidity, and medications from medical databases. We used conditional logistic regression to compute odds ratios (ORs), controlling for potential confounders.
Results:
Among 20,221 patients with atrial fibrillation or flutter, 1288 (6.4%) were current glucocorticoid users and 2375 (11.7%) were former users. Among 202,130 population controls, 5245 (2.6%) were current glucocorticoid users and 19 940 (9.9%) were former users. Current glucocorticoid use was associated with an increased risk of atrial fibrillation or flutter compared with never use (adjusted OR, 1.92; 95% confidence interval [CI], 1.79-2.06). Among new glucocorticoid users, the adjusted OR was 3.62 (95% CI, 3.11-4.22) and among long-term users it was 1.66 (95% CI, 1.53-1.80). The increased risk remained robust in patients with and without pulmonary and cardiovascular diseases. Former glucocorticoid use was not associated with increased risk (adjusted OR, 1.00; 95% CI, 0.96-1.06).
Conclusion:
Current glucocorticoid use was associated with an almost 2-fold increased risk of atrial fibrillation or flutter.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Oral Hypoglycemic Agents: Glinides
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
